Trial Search Results

18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: 18-F FTC 146


Phase 2


Inclusion Criteria:

   - Patients with biopsy proven osteosarcoma requiring local surgical intervention.

   - ECOG ≤ 2

   - Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

   - Chemotherapy in the past 2 months.

   - Prior history of allergic reaction to 18F FTC 146.

   - Pregnant or nursing

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Montes